1. Home
  2. ORTX

ORTX

Orchard Therapeutics plc

Logo Orchard Therapeutics plc

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

0

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

Founded: 2015 Country:
United Kingdom
United Kingdom
Employees: N/A City: LONDON
Market Cap: 380.1M IPO Year: 2018
Target Price: $21.67 AVG Volume (30 days): 107.4K
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.00 EPS Growth: N/A
52 Week Low/High: $4.24 - $16.72 Next Earning Date: 03-04-2024
Revenue: $21,839,000 Revenue Growth: 35.21%
Revenue Growth (this year): 16.38% Revenue Growth (next year): 76.76%

Share on Social Networks: